Seward moves to new premises
Doubles manufacturing and storage facilities
The new building represents a significant investment by the company following the securing of a NatWest/RBS Manufacturing Fund. It will also ensure shorter lead times for the Stomacher sample preparation products for microbiological analyses and tissue processing, the company said.
The premises also house a purpose-built r&d laboratory for product development, application assessment and customer protocol development.
Further investment in web conferencing facilities will also allow training webinars and in-depth technical support to be offered to customers, wherever they are located.
The new premises support a much-needed increase in production capacity, driven by new applications and the opening of Seward Inc in Long Island, New York, US in 2009.
In the first half of 2010, sales of the Stomacher laboratory blenders grew by nearly 20%, compared with the same period in 2009. Sales of the Stomacher 80 biomaster range for small tissue processing increased by 53%, while the large volume Stomacher 3500 saw a 72% growth.
‘We are dedicated to maintaining excellence in our products, customer service and support for our rapidly growing global customer base, so the increased size and capacity of our new premises ensures we can guarantee this now and in the future,’ said Stuart Ray, technical director, Seward Ltd.
He added that the firm had also seen strong growth in the US and Asia/Pacific regions.
You may also like
Trending Articles
You may also like
Manufacturing
![SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs]()
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Portable gas detection in the pharmaceutical sector]()
Portable gas detection in the pharmaceutical sector
Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
![New legal duties for QPs in decentralised manufacturing]()
New legal duties for QPs in decentralised manufacturing
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Manufacturing
![FDA escalates action against Dabur India over systemic data-integrity and cGMP failures]()
FDA escalates action against Dabur India over systemic data-integrity and cGMP failures
The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
Manufacturing
![DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction]()
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction
The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows